

# Genome-Wide Association Study of Coronary Heart Disease and Its Risk Factors in 8,090 African Americans: The NHLBI CARE Project

Guillaume Lettre<sup>1,2</sup>, Cameron D. Palmer<sup>3,4,9</sup>, Taylor Young<sup>3,9</sup>, Kenechi G. Ejebe<sup>3,9</sup>, Hooman Allayee<sup>5</sup>, Emelia J. Benjamin<sup>6,7</sup>, Franklyn Bennett<sup>8</sup>, Donald W. Bowden<sup>9</sup>, Aravinda Chakravarti<sup>10</sup>, Al Dreisbach<sup>11</sup>, Deborah N. Farlow<sup>3</sup>, Aaron R. Folsom<sup>12</sup>, Myriam Fornage<sup>13</sup>, Terrence Forrester<sup>8</sup>, Ervin Fox<sup>11</sup>, Christopher A. Haiman<sup>5</sup>, Jaana Hartiala<sup>5</sup>, Tamara B. Harris<sup>14</sup>, Stanley L. Hazen<sup>15</sup>, Susan R. Heckbert<sup>16,17,18</sup>, Brian E. Henderson<sup>5</sup>, Joel N. Hirschhorn<sup>3,4,19</sup>, Brendan J. Keating<sup>20</sup>, Stephen B. Kritchevsky<sup>21</sup>, Emma Larkin<sup>22</sup>, Mingyao Li<sup>23</sup>, Megan E. Rudock<sup>24</sup>, Colin A. McKenzie<sup>25</sup>, James B. Meigs<sup>19,26</sup>, Yang A. Meng<sup>3</sup>, Tom H. Mosley Jr.<sup>11</sup>, Anne B. Newman<sup>27</sup>, Christopher H. Newton-Cheh<sup>3,7,19,28,29</sup>, Dina N. Paltoo<sup>30</sup>, George J. Papanicolaou<sup>30</sup>, Nick Patterson<sup>3</sup>, Wendy S. Post<sup>31</sup>, Bruce M. Psaty<sup>16,17,18</sup>, Atif N. Qasim<sup>32</sup>, Liming Qu<sup>23</sup>, Daniel J. Rader<sup>32,33</sup>, Susan Redline<sup>23</sup>, Muredach P. Reilly<sup>32,33</sup>, Alexander P. Reiner<sup>34</sup>, Stephen S. Rich<sup>35</sup>, Jerome I. Rotter<sup>36</sup>, Yongmei Liu<sup>24</sup>, Peter Shrader<sup>26</sup>, David S. Siscovick<sup>16,17</sup>, W. H. Wilson Tang<sup>15</sup>, Herman A. Taylor Jr.<sup>11,37,38</sup>, Russell P. Tracy<sup>39</sup>, Ramachandran S. Vasan<sup>6,7</sup>, Kevin M. Waters<sup>5</sup>, Rainford Wilks<sup>40</sup>, James G. Wilson<sup>11,41</sup>, Richard R. Fabsitz<sup>30</sup>, Stacey B. Gabriel<sup>3</sup>, Sekar Kathiresan<sup>3,7,19,28,29</sup>, Eric Boerwinkle<sup>42\*</sup>

**1** Montreal Heart Institute, Montréal, Canada, **2** Département de Médecine, Université de Montréal, Montréal, Canada, **3** Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America, **4** Divisions of Genetics and Endocrinology and Program in Genomics, Children's Hospital Boston, Boston, Massachusetts, United States of America, **5** Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, United States of America, **6** Department of Medicine, Boston University Schools of Medicine and Epidemiology, Boston, Massachusetts, United States of America, **7** Framingham Heart Study of the National Heart, Lung, and Blood Institute and Boston University, Framingham, Massachusetts, United States of America, **8** Tropical Medicine Research Institute, University of the West Indies, Kingston, Jamaica, **9** Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America, **10** McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, **11** Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, United States of America, **12** Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, United States of America, **13** Institute of Molecular Medicine and Division of Epidemiology School of Public Health, University of Texas Health Sciences Center at Houston, Houston, Texas, United States of America, **14** Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, Bethesda, Maryland, United States of America, **15** Departments of Cell Biology and Cardiovascular Medicine, The Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio, United States of America, **16** Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington, United States of America, **17** Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, United States of America, **18** Group Health Research Institute, Group Health Cooperative, Seattle, Washington, United States of America, **19** Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America, **20** Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America, **21** J. Paul Sticht Center on Aging, Division of Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America, **22** Case Western Reserve University, Center for Clinical Investigation, Cleveland, Ohio, United States of America, **23** Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, **24** Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America, **25** Tropical Metabolism Research Unit, Tropical Medicine Research Institute, University of the West Indies, Kingston, Jamaica, **26** General Medicine Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America, **27** Center for Aging and Population Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, **28** Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, United States of America, **29** Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America, **30** National Heart, Lung, and Blood Institute (NHLBI), Division of Cardiovascular Sciences, National Institutes of Health, Bethesda, Maryland, United States of America, **31** Division of Cardiology, the Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, **32** The Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, **33** The Institute for Translational Medicine and Therapeutics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, **34** Department of Epidemiology, University of Washington, Seattle, Washington, United States of America, **35** Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, United States of America, **36** Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America, **37** Jackson State University, Jackson, Mississippi, United States of America, **38** Tougaloo College, Tougaloo, Mississippi, United States of America, **39** Departments of Pathology and Biochemistry, University of Vermont, Colchester, Vermont, United States of America, **40** Epidemiology Research Unit, Tropical Medicine Research Institute, University of the West Indies, Kingston, Jamaica, **41** G. V. (Sonny) Montgomery Veterans Affairs Medical Center, Jackson, Mississippi, United States of America, **42** Human Genetics Center and Institute of Molecular Medicine and Division of Epidemiology, University of Texas Health Science Center, Houston, Texas, United States of America

## Abstract

Coronary heart disease (CHD) is the leading cause of mortality in African Americans. To identify common genetic polymorphisms associated with CHD and its risk factors (LDL- and HDL-cholesterol (LDL-C and HDL-C), hypertension, smoking, and type-2 diabetes) in individuals of African ancestry, we performed a genome-wide association study (GWAS) in 8,090 African Americans from five population-based cohorts. We replicated 17 loci previously associated with CHD or its risk factors in Caucasians. For five of these regions (CHD: *CDKN2A/CDKN2B*; HDL-C: *FADS1-3*, *PLTP*, *LPL*, and *ABCA1*), we could leverage the distinct linkage disequilibrium (LD) patterns in African Americans to identify DNA polymorphisms more strongly associated with the phenotypes than the previously reported index SNPs found in Caucasian populations. We also developed a new approach for association testing in admixed populations that uses allelic and local ancestry variation. Using this method, we discovered several loci that would have been missed using the basic allelic and global ancestry information only. Our conclusions suggest that no major loci uniquely explain the high prevalence of CHD in African Americans. Our project has developed resources and methods that address both admixture- and SNP-association to maximize power for genetic discovery in even larger African-American consortia.

**Citation:** Lettre G, Palmer CD, Young T, Ejebe KG, Allayee H, et al. (2011) Genome-Wide Association Study of Coronary Heart Disease and Its Risk Factors in 8,090 African Americans: The NHLBI CARE Project. *PLoS Genet* 7(2): e1001300. doi:10.1371/journal.pgen.1001300

**Editor:** Mark I. McCarthy, University of Oxford, United Kingdom

**Received:** July 22, 2010; **Accepted:** January 7, 2011; **Published:** February 10, 2011

This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

**Funding:** The grants and contracts that have supported CARE are listed at <http://public.nhlbi.nih.gov/GeneticsGenomics/home/care.aspx>, including HHSN268200625226C (ADB No. N01-HC-65226). Additional support for this work was provided by: the Fondation de l'Institut de Cardiologie de Montreal and the Centre of Excellence in Personalized Medicine (CEPMed) (to GL), NIDDK K24 DK080140 (to JBM). The Health ABC study was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106. The Health ABC genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences, and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. The Health ABC research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. The Cleveland Clinic GeneBank study was supported through NIH grants 1P01HL098055-01, P01HL087018, P01HL076491, R01DK080732, and R01HL103931-01. A portion of analyses for the Cleveland Clinic GeneBank was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Number C06 (RR10600-01, CA62528-01, RR14514-01) from the National Center for Research Resources. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** JBM has a research grant from GSK and a consulting agreement with Interleukin Genetics, SLH reports being listed as co-inventor on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics. SLH reports having been paid as a consultant or speaker for the following companies: AstraZeneca Pharmaceuticals LP, BG Medicine, Merck & Co., Pfizer Takeda, Esperion, and Cleveland Heart Lab. SLH reports receiving research funds from Abbott, Liposcience, and Cleveland Heart Lab. WHWT reports receiving research grant support from Abbott Laboratories.

\* E-mail: Eric.Boerwinkle@uth.tmc.edu

These authors contributed equally to this work

## Introduction

Coronary heart disease (CHD) is the leading cause of mortality in African-American men and women [1]. The risk factors for CHD in African Americans are similar to those reported in Caucasians, but their relative impact varies between the two ethnic groups. Multiple studies have reported that smoking, type-2 diabetes (T2D), hypertension, and LDL- and HDL-cholesterol (LDL-C and HDL-C) are significant independent risk factors for CHD in African Americans [2–5]. In general, hypertension and LDL-C have a larger and smaller impact on CHD risk, respectively, in African Americans compared with Caucasians [3]. There is also extensive evidence of the role of genetic factors in the familial aggregation of CHD and its predictors in African Americans [6]. However, the underlying genes remain largely unknown.

Recent advances in genome-wide association studies (GWAS) have made spectacular advances in identifying genes contributing to numerous common chronic diseases in Europeans and European Americans [7]. There are multiple loci convincingly associated with CHD risk in Caucasians, including many genes involved in lipid metabolism, as well as novel chromosomal regions that do not appear to contribute to risk through traditional risk factors [7–14]. However, there have been no large-scale GWAS for CHD and its risk factors in African Americans. GWAS in African Americans is important because new genes may be identified as a result of genetic variation private to populations of

African-descent, differences in allele frequencies and in patterns of linkage disequilibrium (LD), differences in the relative impact of risk factors to disease, or differences in gene-environment interactions. Here we report a large (and for most phenotypes first) GWAS for CHD, type-2 diabetes (T2D), hypertension, LDL-C and HDL-C, and smoking in 8,090 African Americans as part of the National Heart, Lung, and Blood Institute (NHLBI)-sponsored Candidate gene Association Resource (CARE) Project [15].

## Results

We genotyped 909,622 single nucleotide polymorphisms in 9,119 African Americans from the ARIC (N = 3,269), CARDIA (N = 1,209), CFS (N = 704), JHS (N = 2,200), and MESA (N = 1,737) population-based cohorts, on the Affymetrix Genome-Wide Human SNP Array 6.0 platform. Genotypes were called using Birdseed v1.33 [16], and stringent quality-control filters were applied (Tables S1 and S2). For samples that passed quality control (N = 8,100), principal component analysis (PCA) using EIGENSTRAT [17] revealed only ten population outliers across all cohorts; these samples were also excluded from the analysis (Text S1 and Figure S1). Overall, a total of 8,090 African Americans with very high genotype quality (average genotype success rate of 99.65%) were available for analysis. The demographics of these participants by cohort are shown in Table 1. To increase our coverage of common genetic variation and statistical power, and to facilitate comparisons across

## Author Summary

To date, most large-scale genome-wide association studies (GWAS) carried out to identify risk factors for complex human diseases and traits have focused on population of European ancestry. It is currently unknown whether the same loci associated with complex diseases and traits in Caucasians will replicate in population of African ancestry. Here, we conducted a large GWAS to identify common DNA polymorphisms associated with coronary heart disease (CHD) and its risk factors (type-2 diabetes, hypertension, smoking status, and LDL- and HDL-cholesterol) in 8,090 African Americans as part of the NHLBI Candidate gene Association Resource (CARE) Project. We replicated 17 associations previously reported in Caucasians, suggesting that the same loci carry common DNA sequence variants associated with CHD and its risk factors in Caucasians and African Americans. At five of these 17 loci, we used the different patterns of linkage disequilibrium between populations of European and African ancestry to identify DNA sequence variants more strongly associated with phenotypes than the index SNPs found in Caucasians, suggesting smaller genomic intervals to search for causal alleles. We also used the CARE data to develop new statistical methods to perform association studies in admixed populations. The CARE Project data represent an extraordinary resource to expand our understanding of the genetics of complex diseases and traits in non-European-derived populations.

genotyping platforms, we imputed genotypes in the CARE African-American populations using MACH taking into account the admixed nature of the population (Text S1) [18,19].

For all cohorts except CFS, single marker genetic association tests were performed by study using PLINK v1.06 [20] under an additive genetic model. We used linear regression for quantitative traits (HDL-C, LDL-C, and smoking) and logistic regression for dichotomous phenotypes (CHD, hypertension, and T2D). For CFS, family structure was modeled using linear mixed effects (LME) models and generalized estimating equations (GEE) for quantitative and dichotomous phenotypes, respectively [21]. For all analyses, the first ten principal components were used as covariates to account for global admixture and population stratification. A detailed description of the analysis methods and the phenotypic definitions used can be found in Text S1. Power calculations for the different phenotypes analyzed are summarized in Table S3; we have excellent power to find strong signals, but low to modest power for variants with weak phenotypic effects. The inflation factors ( $\lambda_g$ ) observed were all near unity (Table S4), suggesting that most confounders, including population stratification, were well-controlled.

We applied genomic control to the individual cohorts' results and combined them using the inverse variance meta-analysis method [22]. Inflation factors of the meta-analysis results were modest and were again scaled using genomic control (Table S4). Quantile-quantile (QQ) plots of the six different meta-analyses after double genomic control corrections show that the test statistics follow the null expectations, except for the HDL-C and LDL-C meta-analyses, which show an upward departure from the null distributions at the lowest P-values (Figure 1). This departure is caused by known genetic variants with large effects on lipid levels (Figure S2).

The main goal of this study was to identify new genetic risk factors for CHD and its predictors in African Americans. For five


**Table 1.** Demographics of the CARE and replication African-American cohorts.

Phenotypes <sup>1</sup>	ARIC	CARDIA	CFS	JHS	MESA	MEC-T2D	Cleveland Clinic	PennCATH	NHANESIII	Jamaica SPT	Jamaica GXE	Health ABC
Gender	1045/1785	366/583	213/308	842/1302	745/901	835/1349	345/374	280/222	718/1002	674/1055	232/736	468/651
Age	53.3±5.8	24.4±3.8	45.7±16.2	50.0±12.2	62.2±10.1	60.4±8.5	60.0±11.1	58.0±10.6	40.8±16.7	46.1±13.9	39.7±8.3	73.4±2.9
Coronary heart disease	110/2580	NA	25/475	125/1998	NA	NA	220/400	157/334	NA	NA	NA	244/895
Type-2 diabetes	529/2150	NA	98/403	339/1777	298/1348	1070/1114	NA	NA	168/899	NA	NA	335/757
Hypertension	1612/1132	36/913	209/260	1193/918	1019/625	NA	NA	NA	501/1219	NA	NA	871/263
LDL-C	138.7±43.3 (2588)	111.3±31.0 (940)	99.0±33.9 (295)	125.2±36.6 (2111)	116.5±33.4 (1631)	NA	NA	NA	121.1±40.4 (805)	123.5±39.1 (928)	136.6±38.5 (928)	123.9±36.7 (1128)
HDL-C	54.7±17.5 (2613)	54.4±13.0 (940)	46.4±15.0 (483)	50.0±14.1 (2138)	52.5±15.3 (1639)	NA	NA	NA	54.1±17.2 (805)	48.4±12.6 (1413)	51.5±11.5 (967)	57.1±17.6 (1138)
Smoking	14.2±9.4 (799)	10.8±7.6 (359)	10.8±6.7 (178)	15.1±11.6 (659)	14.6±18.6 (873)	NA	NA	NA	NA	NA	NA	NA

<sup>1</sup>For gender, we report the number of males/females. For age, we report the mean ± standard deviation in years. For coronary heart disease, type-2 diabetes, and hypertension, we report the number of cases/controls. For LDL-C and HDL-C, we report the mean ± standard deviation in mg/dl (number of samples with phenotypes available). For smoking, we report the mean ± standard deviation in daily cigarettes, excluding non-smokers (number of samples with phenotypes available). The number of CHD cases with concomitant type-2 diabetes in the CARE cohorts is: 44 for ARIC, 14 for CFS, and 43 for JHS. NA; not available or not analyzed in this study.

doi:10.1371/journal.pgen.1001300.t001





**Figure 1. Quantile-quantile (QQ) plots of the meta-analyses for coronary heart disease, HDL-C, hypertension, LDL-C, smoking, and type-2 diabetes analyzed in the CARE African-American samples (N = 8,090).** Each black circle represents an observed statistic for all genotypes and imputed SNPs (defined as the  $-\log_{10}(P\text{-value})$ ) against the corresponding expected statistic. The grey area corresponds to the 90% confidence intervals calculated empirically using permutations. The meta-analysis inflation factors are: coronary heart disease ( $\lambda_s = 0.991$ ), HDL-C ( $\lambda_s = 1.030$ ), hypertension ( $\lambda_s = 1.024$ ), LDL-C ( $\lambda_s = 1.023$ ), smoking ( $\lambda_s = 1.008$ ), and type-2 diabetes ( $\lambda_s = 1.017$ ). Data shown are genomic controlled before (for each study) and after the meta-analysis. doi:10.1371/journal.pgen.1001300.g001

traits analyzed (we could not identify African-American replication cohorts for smoking), we identified SNPs with the strongest evidence of association in the CARE meta-analysis – SNPs were selected after accounting for LD to limit association signals redundancy – and sought replication using *in silico* data or direct genotyping in independent African-American cohorts (Table 1).

Combined results from a meta-analysis of the CARE and replication data are presented in Tables S5, S6, S7, S8, S9 and summarized in Table 2. We identified one novel locus that reached the generally accepted level for genome-wide significance ( $P \leq 5 \times 10^{-8}$ ): SNP rs7801190 in the potassium/chloride transporter gene *SLC12A9* and hypertension (OR = 1.31, combined  $P = 3.4 \times 10^{-8}$ ). Despite reaching genome-wide significance, we

are cautious in highlighting this association because it was identified using imputed genotypes (imputation quality  $r^2_{\text{hat}} = 0.70$ ) and the replication result, also obtained by imputation, was not statistically significant ( $P = 0.29$ ). Indeed, when we directly assessed the quality of the imputation by directly genotyping rs7801190 in ARIC African-American samples (N = 2,572), we failed to validate the observed association with hypertension. This result suggests that the association between rs7801190 and hypertension status observed in the CARE African-American datasets is likely due to chance.

To validate our phenotype modeling and analytical strategy, we sought to replicate in the CARE meta-analyses genetic associations previously reported in populations of European ancestry. We retrieved all index SNPs associated at genome-wide significance

**Table 2.** Novel genetic associations ( $P \leq 1 \times 10^{-6}$ ) between SNPs and coronary heart disease or its risk factors in African Americans.

Trait	SNP	CHR (POS) <sup>1</sup>	Reference allele (reference allele frequency) <sup>2</sup>	CARE meta-analysis		Replication		Combined		Locus
				OR [95% CI] or Beta (SE) <sup>3</sup>	P-value <sup>4</sup>	OR [95% CI] or Beta (SE) <sup>3</sup>	P-value	OR [95% CI] or Beta (SE) <sup>3</sup>	P-value	
HDL-C	rs7323893	13 (87502707)	T (0.91)	-0.138 (0.030)	$5.7 \times 10^{-6}$	-0.131 (0.047)	0.0053	-0.136 (0.025)	$1.3 \times 10^{-7}$	
	rs937254	15 (55697456)	A (0.57)	0.077 (0.017)	$5.4 \times 10^{-6}$	0.078 (0.043)	0.067	0.077 (0.016)	$1.0 \times 10^{-6}$	<i>GCMI1</i>
Hypertension	rs7801190	7 (100296029)	C (0.73)	1.35 [1.22–1.50]	$2.5 \times 10^{-8}$	1.13 [0.90–1.44]	0.29	1.31 [1.19–1.44]	$3.4 \times 10^{-8}$	<i>SLC12A9</i>
LDL-C	rs13161895	5 (179403807)	T (0.08)	0.151 (0.035)	$2.3 \times 10^{-5}$	0.139 (0.052)	0.0077	0.147 (0.029)	$5.8 \times 10^{-7}$	<i>RNF130</i>

<sup>1</sup>Coordinates are on NCBI build 36.1.

<sup>2</sup>Average frequency for the reference allele across all available African-American CARE samples.

<sup>3</sup>Direction of the effect given for the reference allele; OR, odds ratio; CI, confidence interval; SE, standard error.

<sup>4</sup>P-values are scaled using genomic control.

doi:10.1371/journal.pgen.1001300.t002

level with CHD, T2D, hypertension, HDL-C, LDL-C, and smoking in Caucasians as well as their proxy SNPs (defined as markers with an  $r^2 \geq 0.5$  with the index SNPs in HapMap samples of European ancestry (CEU)) (Table S10) [23]. We then determined whether there was also evidence of association for the same signals in this large sample of African Americans. We detected modest to strong evidence of replication for one locus associated with CHD, one locus with T2D, nine with HDL-C, and six with LDL-C (Table 3 and Table S11). We did not replicate signals associated with smoking or hypertension. Furthermore, the top ten associated SNPs in a recent hypertension GWAS performed in African Americans [24] were not associated with hypertension in the CARE meta-analysis (different direction of effect and/or  $P > 0.05$ ). Since these hypertension association signals did not replicate in the original publication, non-replication here may result from their being falsely positive in the original report. Although replication of some of the above loci in African-derived populations had been reported previously [25], for most of them, the CARE results represent the first replication in populations of African ancestry.

Taking advantage of the LD patterns in African Americans (LD breakdown over shorter distances compared with Caucasians), we assessed whether we could fine-map some of the associations previously reported in Caucasians. For this, we evaluated SNPs that were correlated with the index SNP in HapMap CEU ( $r^2 \geq 0.5$ ), but largely uncorrelated with it in HapMap samples of African descent (YRI) ( $r^2 \leq 0.1$ ). In most cases, the same signals were responsible for the associations in Caucasians and African Americans (Table 3 and Table S11). However, we found five examples where the predominant association signals were at SNPs strongly correlated with the index SNPs in HapMap CEU but weakly or not correlated with the index SNPs in HapMap YRI: the *CDKN2A/CDKN2B* locus for CHD and the *FADS1-3*, *PLTP*, *LPL*, and *ABCA1* loci for HDL-C (Table S12). Using available genetic association results for myocardial infarction [10] and HDL-C [26] in Caucasians, we illustrate in Figure 2 and Figure S3 how our results in African Americans can help refine association signals. For instance, for the *FADS* locus, the index SNP in Caucasians (rs174547) is in strong LD with the top SNP in the CARE African-American meta-analysis (rs1535) in HapMap CEU ( $r^2 = 1$ ) but not in HapMap YRI ( $r^2 = 0.09$ ). The region of strong

LD around rs174547 in HapMap CEU is 113 kb wide and includes the three *FADS* genes, whereas rs1535, located in an intron of *FADS2*, is in strong LD with no other markers in HapMap YRI (Figure 2). Comparison of association signals regionally in African Americans and European-derived individuals can thus be useful in two ways: (1) they may suggest smaller chromosomal regions for re-sequencing experiments to attempt to identify causal variant(s) that underlie shared signals between African- and European-derived chromosomes or (2) they may indicate that the index SNPs for African and European populations are linked to distinct causal variants. A third potentially interesting result from trans-ethnic comparison of association results is the identification of ethnic-specific association signals. For instance, at the *ABCA1* locus, three SNPs in LD (rs4743763, rs4149310, and rs2515629) are associated with HDL-C in CARE African Americans ( $P < 1 \times 10^{-5}$ ), but not in Caucasians (Figure S3D).

The optimal analytical strategy for GWAS in recently admixed populations has not been established. In African Americans, an ideal test statistic would incorporate both genotype information as traditionally used in GWAS, but also, at each locus, the probability that a given individual has zero, one, or two copies of a European (or African) chromosomal segment. This method would be particularly informative in a case where, for example, the causal allele is not in LD with any markers on the genotyping array, but is at higher frequency on one ancestral background. To explore the benefits of such a statistical framework, we designed and applied a novel method that combines evidence of association from genotypes and local ancestry estimates; the method is described in details in Text S1. Briefly, we use a panel of ancestry informative markers across the genome and a new implementation of the software ANCESTRYMAP [27] to estimate, for each of the CARE African Americans genotyped, the probabilistic proportion of European ancestry (0–100%) at the locus for each of the ~900,000 SNPs genotyped on the Affy6.0 platform. For each SNP, we can then compute association between the phenotype and both the SNP genotype and the SNP estimate of local ancestry to generate a combined score that summarizes allelic variation and admixture. This method was used to produce the association data presented in Table 4.

Our method to assess combined SNP- and ancestry-association was tested explicitly on CHD and its risk factors in the CARE African-



**Table 3.** Replication of associations previously reported in Caucasians in the CARE African-American meta-analyses.

Trait	Locus	Chr.	CARE SNP <sup>a</sup>	Position <sup>b</sup>	Effect allele <sup>c</sup>	Average effect allele frequency in CARE (SE)	Odds ratio/Beta <sup>d</sup>	95% CI/SE <sup>d</sup>	P-value <sup>e</sup>	Reference
Coronary heart disease	<i>CDKN2A, CDKN2B</i>	9	rs4977574	22088574	G	0.177 (0.004)	1.18 (OR)	[0.93–1.49]	0.17	[10]
		9	rs6475606 (p)	22071850	C	0.109 (0.003)	2.00 (OR)	[1.34–2.96]	$6.4 \times 10^{-4}$	
Type-2 diabetes	<i>TCF7L2</i>	10	rs7903146	114748339	T	0.291 (0.005)	1.33 (OR)	[1.19–1.48]	$3.5 \times 10^{-7}$	[29]
HDL-C	<i>GALNT2</i>	1	rs2144300	228361539	T	0.143 (0.012)	0.092 (BETA)	0.029	0.0015	[13]
	<i>PPP1R3B</i>	8	rs9987289	9220768	A	0.191 (0.005)	−0.090 (BETA)	0.022	$4.3 \times 10^{-5}$	[30]
	<i>LPL</i>	8	rs10503669	19891970	A	0.059 (0.006)	0.137 (BETA)	0.035	$7.2 \times 10^{-5}$	[13]
			rs10096633 (p)	19875201	T	0.430 (0.039)	0.101 (BETA)	0.017	$1.5 \times 10^{-9}$	
	<i>ABCA1</i>	9	rs3905000	106696891	A	0.161 (0.011)	−0.043 (BETA)	0.022	0.054	[31]
			rs13284054 (p)	106708894	C	0.850 (0.005)	0.090 (BETA)	0.027	0.0011	
	<i>FADS1, FADS2, FADS3</i>	11	rs174547	61327359	C	0.092 (0.009)	−0.055 (BETA)	0.030	0.068	[26]
			rs1535 (p)	61354548	A	0.820 (0.009)	−0.102 (BETA)	0.025	$6.7 \times 10^{-5}$	
	<i>LIPC</i>	15	rs1800588	56510967	T	0.497 (0.017)	0.102 (BETA)	0.018	$1.5 \times 10^{-8}$	[32]
			rs8034802 (p)	56512084	A	0.362 (0.010)	0.104 (BETA)	0.017	$1.3 \times 10^{-9}$	
	<i>CETP</i>	16	rs3764261	55550825	A	0.305 (0.010)	0.203 (BETA)	0.023	$8.6 \times 10^{-18}$	[13]
			rs247617 (n)	55548217	A	0.258 (0.006)	0.260 (BETA)	0.019	$1.2 \times 10^{-43}$	
	<i>LCAT</i>	16	rs255052	66582496	A	0.218 (0.009)	0.132 (BETA)	0.020	$6.6 \times 10^{-11}$	[13]
			rs7679	44009909	T	0.958 (0.005)	0.052 (BETA)	0.041	0.22	[26]
<i>PLTP</i>		rs6065904 (p)	43968058	A	0.202 (0.010)	−0.0904 (BETA)	0.023	$7.4 \times 10^{-5}$		
LDL-C	<i>DOCK7</i>	1	rs10889353	62890784	A	0.618 (0.012)	0.049 (BETA)	0.017	0.0040	[31]
			rs10889335 (p)	62732689	A	0.606 (0.018)	0.068 (BETA)	0.018	$1.2 \times 10^{-4}$	
	<i>CELSR2, PSRC1, SORT1</i>	1	rs12740374	109619113	T	0.235 (0.003)	−0.174 (BETA)	0.021	$1.3 \times 10^{-16}$	[26]
	<i>PCSK9</i>	1	rs10493178 (n)	55369655	A	0.878 (0.007)	0.177 (BETA)	0.025	$4.7 \times 10^{-12}$	
	<i>APOB</i>	2	rs562338	21141826	A	0.598 (0.009)	−0.089 (BETA)	0.017	$3.1 \times 10^{-7}$	[32]
			rs503662 (p)	21267647	T	0.652 (0.010)	−0.110 (BETA)	0.018	$2.5 \times 10^{-9}$	
	<i>LDLR</i>	19	rs6511720	11063306	T	0.144 (0.002)	−0.208 (BETA)	0.038	$7.2 \times 10^{-8}$	[26]
<i>APOE, APOC1, APOC4, APOC2</i>	19	rs1160985 (n)	50095252	T	0.635 (0.011)	−0.166 (BETA)	0.017	$7.2 \times 10^{-21}$		

To be included in this table, we require a two-tailed  $P \leq 0.05$  after Bonferroni correction for the number of independent loci reported in the NHGRI database (Table S5). We report the association results for the published (index) SNP, unless it is not available. In that case, we report results for a proxy SNP ( $r^2 \geq 0.5$  with original SNP in HapMap CEU; see Table S5 for additional details).

<sup>a</sup>Proxy SNPs are marked with (p). SNPs that have a strong association signal but are not in LD with the published SNP are marked with (n) as potentially novel.

<sup>b</sup>Position on NCBI build 36.1.

<sup>c</sup>Effect alleles are given on the forward strand. For proxy SNPs, we phased HapMap CEU genotypes for the index and proxy SNPs to determine haplotypes, to be able to assess consistency of the direction of effect.


<sup>d</sup>For dichotomous phenotypes, we report odds ratio (OR) and 95% confidence interval (CI); for quantitative traits, we report effect size (beta, in standard deviation units) and standard error (SE).

<sup>e</sup>P-values are corrected using genomic control.

doi:10.1371/journal.pgen.1001300.t003

American samples (Figures S4, S5). For each SNP, we compared the test statistic obtained using the SNP-alone or the SNP+admixture information (in both methods, global ancestry is included as a covariate), focusing on markers that would not have been prioritized for follow-up replication when considering only SNP genotype association results (Figure S6). Across the six phenotypes, we identified 12 SNPs outside the previously known loci with a  $P \leq 1 \times 10^{-6}$  in this SNP+admixture test statistic (Table 4). Most of these SNPs have a large allele frequency difference between the HapMap CEU and YRI individuals, suggesting that local ancestry might confound simple SNP association testing. For instance, the frequency of the C-allele at

rs8078633 near the *APPBP2* gene is 100% and 18% in CEU and YRI, respectively. The association between this SNP and HDL-C levels is weak when considering only allelic variation ( $P = 0.98$ ) but becomes highly significant when evidence from the genotype and the estimate of local ancestry is combined ( $P = 3.6 \times 10^{-7}$ ) (Table 4). This composite approach also identified a SNP near the phospholipase B1 gene (*PLB1*) that is strongly associated with LDL-C levels ( $P = 4.1 \times 10^{-8}$ ), but that would not have been noticed using traditional genotype-only association testing ( $P = 0.23$ ) (Table 4). As more large-scale GWAS in individuals of African ancestry are completed, it will be important to replicate these results.



**Figure 2. HDL-C association results in Caucasians (top panel) [26] and in the CARE African Americans (bottom panel) at the *FADS* locus.** Plots were generated using LocusZoom [33]. Under the top panel, the light blue box corresponds to the chromosomal interval flanked by the leftmost and rightmost SNPs with a  $r^2 \geq 0.3$  with the index SNP rs174547 in HapMap CEU. In the bottom panel, there is no light blue box because the top CARE SNPs at this locus, rs1535, is not in strong LD with any markers in HapMap YRI. doi:10.1371/journal.pgen.1001300.g002

**Discussion**

Most large-scale genetic efforts to identify risk factors for CHD have focused so far on populations of European ancestry. Given the prevalence of the disease in African Americans, and the development of better genotyping platforms that more completely survey common genetic variation in African-derived genomes [16], it is now both pertinent and timely to investigate the genetics of CHD in populations of African ancestry. The CARE Project was launched four years ago with the specific goal to create a resource for association studies of various heart-, lung-, and blood-related phenotypes across different ethnic groups [15]. In this article, we present results from the largest GWAS to date for CHD and its risk factors in African Americans. Despite being the largest, the size of our GWAS is modest compared to that of some European-derived consortia. As a consequence, we had limited discovery power and did not identify novel loci specifically

associated with CHD or its risk factors that reach genome-wide significance in our African-American dataset.

We also attempted to replicate in the CARE African-American participants genetic associations to CHD and its risk factors previously identified in Caucasians. We could replicate 17 of those associations; for many of them, this was the first replication in a non-European-derived population (Table 3). For five of these 17 associations, we showed how cross-ethnic comparisons of genetic association results may help refine genomic intervals carrying causal alleles (Figure 2 and Figure S3). There were, however, a large number of loci originally found in Caucasians that were not replicated in the CARE meta-analyses presented in this manuscript (Table S11). Because our sample size was relatively modest, that we used stringent statistical thresholds to declare replication in order to control our false positive rate, and that effect sizes could be weaker for given loci across different ethnic groups, our limited power probably explains why

**Table 4.** Top novel associations ( $P \leq 1 \times 10^{-6}$ ) identified using SNP genotype and estimate of local African versus European ancestry.

TRAIT	SNP	CHR (POS) <sup>1</sup>	Reference allele	Reference allele frequency			SNP-only		SNP+Estimate of local ancestry			Closest genes <sup>7</sup>
				CARE <sup>2</sup>	CEU	YRI	Beta (SE) <sup>3</sup>	P-value <sup>4</sup>	Z <sub>geno</sub> <sup>5</sup>	Z <sub>loc.anc</sub> <sup>6</sup>	P-value <sup>4</sup>	
Coronary heart disease	rs6674681	1 (79493711)	T	0.75	0.23	0.88	0.0892 (0.1151)	0.44	3.524	-4.14	$3.8 \times 10^{-7}$	
	rs6753112	2 (231895399)	T	0.87	0.31	0.91	-0.2459 (0.1357)	0.07	-3.977	3.625	$5.2 \times 10^{-7}$	ARMC9
HDL-C	rs8078633	17 (559286)	C	0.31	1.00	0.18	-0.0006 (0.0186)	0.98	-3.893	4.723	$3.6 \times 10^{-7}$	APPBP2
Hypertension	rs10218356	23 (19168233)	A	0.20	0.94	0.04	-0.0915 (0.0523)	0.08	-4.056	3.891	$6.5 \times 10^{-7}$	
LDL-C	rs17441606	2 (19431916)	A	0.17	0.32	0.11	-0.0759 (0.0219)	$6.2 \times 10^{-4}$	-4.234	4.021	$4.0 \times 10^{-8}$	OSR1
	rs9306885	2 (19852313)	T	0.26	0.72	0.16	-0.0329 (0.0197)	0.10	-4.144	4.321	$1.7 \times 10^{-8}$	
	rs6728440	2 (19862827)	A	0.96	0.87	1.00	0.0978 (0.0446)	0.03	3.527	-4.029	$5.9 \times 10^{-8}$	TTC32
	rs7560236	2 (22930288)	T	0.06	0	0.08	0.1493 (0.0366)	$5.5 \times 10^{-5}$	4.568	3.804	$2.1 \times 10^{-8}$	
	rs6748157	2 (28586865)	A	0.86	0.51	0.98	0.03 (0.0247)	0.23	3.592	-4.062	$4.1 \times 10^{-8}$	PLB1
Smoking	rs7075036	10 (16904816)	T	0.69	0.32	0.80	-0.1326 (0.0296)	$8.4 \times 10^{-6}$	-5.036	2.054	$8.0 \times 10^{-7}$	RSU1, CUBN
	rs11088655	21 (18128360)	T	0.41	0.22	0.52	0.0938 (0.0275)	$6.9 \times 10^{-4}$	4.347	3.637	$2.4 \times 10^{-7}$	C21orf91
	rs16982414	21 (28711411)	T	0.90	0.99	0.84	-0.1646 (0.0432)	$1.5 \times 10^{-4}$	-4.375	-3.327	$6.0 \times 10^{-7}$	

Global ancestry is included in the model for both methods.

<sup>1</sup>Coordinates are on NCBI build 36.1.

<sup>2</sup>Average frequency for the reference allele across all available African American CARE samples.

<sup>3</sup>Direction of the effect given for the reference allele; SE, standard error.

<sup>4</sup>P-values are scaled using genomic control.

<sup>5</sup>Z-score for the SNP genotype information. A Z-score >0 means that the trait (or the risk to develop the disease) increases with the number of copies of reference alleles.

<sup>6</sup>Z-score for the local ancestry estimate information. A Z-score >0 means that the trait (or the risk to develop the disease) increases with the number of copies of European chromosomes.

<sup>7</sup>Genes in a 200 kb window.

doi:10.1371/journal.pgen.1001300.t004

many loci did not replicate in the CARE African Americans. Alternatively, some of these non-replications could be explained by the absence of variants within these loci associated with these traits in African Americans. Our data does not allow us to distinguish these two possibilities, and larger replication studies in African-American cohorts will be needed to draw informative conclusions.

Taken together, our results suggest that CHD risk in African Americans is not influenced by loci with major phenotypic effect on disease risk, but rather by multiple variants of weak effect, as we have observed for CHD and other traits in Caucasians. Because opportunities for replication and meta-analysis with other African-American cohorts are evolving rapidly, the CARE dataset is an outstanding public resource that provides a strong base for discovery of genetic contributors to CHD in non-European-derived populations.

## Materials and Methods

### Ethics statement

All participants gave informed written consent. The CARE project is approved by the ethic committees of the participating studies and of the Massachusetts Institute of Technology.

## Studies

African-American participants for the GWAS were drawn from five population-based studies: Atherosclerosis Risk in Communities (ARIC; N = 3,269), Coronary Artery Risk Development in young Adults (CARDIA; N = 1,209), Cleveland Family Study (CFS; N = 704), Jackson Heart Study (JHS; N = 2,200), and Multi-Ethnic Study of Atherosclerosis (MESA; N = 1,737). Although longitudinal data is available for most participants, only information collected at recruitment was considered in this GWAS. Replication results for top SNP associations were obtained using *in silico* or *de novo* genotyping from four African-American and African-Caribbean population-based cohorts (Health, Aging, and Body Composition Study (Health ABC; N = 1,119), National Health and Nutrition Examination Survey III (NHANES III, N = 1,720), Jamaica Spanish Town (SPT, N = 1,746) and Jamaica GXE (N = 969), one nested case-control panel from the population-based Multiethnic Cohort (MEC, N = 2,184), and two case-control panels (Cleveland Clinic, N = 620, and PennCATH, N = 491). A detailed description of all cohorts and phenotype definitions used in this study is provided in Text S1.



## Genotyping and quality controls

All discovery samples (GWAS) were genotyped on the Affymetrix Genome-Wide Human SNP array 6.0 according to the manufacturer's protocol. For replication, the MEC samples were genotyped by Taqman, and the NHANES III, Jamaica SPT, Jamaica GXE, Cleveland, and UPENN samples were genotyped using Illumina's Oligos Pool All (OPA) technology. The Health ABC samples were genotyped on the Illumina Human1M-Duo BeadChip array as part of an independent GWAS; SNP results for the replication of the CARE findings were extracted and analyzed. Several quality control (QC) filters were applied to the genome-wide genotype data: DNA concordance checks; sample and SNP genotyping success rate (>95%, minor allele frequency  $\geq 1\%$ ); sample heterozygosity rate, identity-by-descent analysis to identify population outliers (Figure S1), problematic samples, and cryptic relatedness; Mendel errors rate in CFS and JHS, and SNP association with chemistry plates. For replication, SNPs and samples with genotyping success rate <90% were excluded. Because of the admixed nature of the participants, SNPs were not removed solely because they departed from Hardy-Weinberg equilibrium. A detailed description of the quality control checks applied to the discovery (GWAS) and replication genotyping data can be found in Text S1.

## SNP imputation

To increase coverage and facilitate comparison with other datasets, we imputed genotype data using MACH v1.0.16 [19]. We built a panel of reference haplotypes using HapMap phase II CEU and YRI data, and imputed SNP genotypes using all Affymetrix 6.0 SNPs that passed the QC steps described above. Using an independent dataset of  $\sim 12,000$  SNPs genotyped on the same DNA but with a different platform, we estimated an allelic concordance rate of 95.6% (Text S1).

## Association analyses

SNP-only based genetic association analysis of quantitative (HDL-C, LDL-C, smoking) and dichotomous (coronary heart disease, type-2 diabetes, hypertension) traits were carried out using linear and logistic statistical framework, respectively, in PLINK (unrelated cohorts: ARIC, CARDIA, JHS, MESA, UPENN, Cleveland, MEC, NHANES III, and Health ABC) or using R scripts that model family structure (related cohort: CFS) [28]. For the cohorts with genome-wide genotyping data available, the first ten principal components were included in each analysis to account for population stratification and admixture. The method to estimate local ancestry was implemented in ANCESTRYMAP and is described in details in Text S1. To combine allelic and local ancestry information (Table 4), we calculated a chi-square statistic with two degrees-of-freedom. Association results were combined across cohorts using an inverse variance meta-analysis approach as implemented in meta.

## URL

CARE: [http://www.broadinstitute.org/gen\\_analysis/care/index.php/Main\\_Page](http://www.broadinstitute.org/gen_analysis/care/index.php/Main_Page); MACH: <http://www.sph.umich.edu/csg/abecasis/MACH/>; METAL: <http://www.sph.umich.edu/csg/abecasis/Metal/index.html>; PLINK: <http://pngu.mgh.harvard.edu/~purcell/plink>.

## Supporting Information

**Figure S1** Plots of the two main principal components (PC) in the CARE African-American samples. European-Americans and Nigerians samples are used as reference populations. We note that the first principal component (PC1) captures European vs. African global ancestry. For CFS, outliers on PC2 all belong to the same large family. Found at: doi:10.1371/journal.pgen.1001300.s001 (0.25 MB TIF)

**Figure S2** Manhattan plots summarizing the meta-analysis results for the six phenotypes analyzed after double genomic control scaling. The dashed line highlights genome-wide significance ( $P\text{-value} = 5 \times 10^{-8}$ ). The genome-wide significant loci include 8p23 (chr8), *LPL* (chr8), *LIPC* (chr15), *LCAT* (chr16), and *CETP* (chr16) for HDL-C, *SLC12A9* (chr7) for hypertension, and *PCSK9* (chr1), *CELSR2-PSRC1-SORT1* (chr1), and *APOE* (chr19) for LDL-C.

Found at: doi:10.1371/journal.pgen.1001300.s002 (1.27 MB TIF)

**Figure S3** Graphical representation of the information summarized in Table S12. Plots were drawn using LocusZoom [26]. CHD association results in Caucasians are from Kathiresan et al. [27]. HDL-C association results in Caucasians are from Kathiresan et al. [28]. Under each plot, the light blue box corresponds to the genomic intervals flanked by the leftmost and rightmost SNPs with  $r^2 \geq 0.3$  with the index SNPs (purple diamond). For the results in Caucasians, we used LD based on HapMap CEU, and for the results in African Americans, LD based on HapMap YRI. For the *PLTP* and *ABCA1* loci, the CARE SNPs (respectively rs6065904 and rs13284054) define genomic intervals of 0.2 kb using the  $r^2 \geq 0.3$  threshold, which appear as light blue lines on the plots.

Found at: doi:10.1371/journal.pgen.1001300.s003 (1.59 MB TIF)

**Figure S4** Quantile-quantile (QQ) plots of the meta-analyses results that take into account local ancestry estimates and SNP genotypes (Chi-square with two degrees-of-freedom ( $N = 8,090$ )). Each black circle represents an observed statistic for genotyped SNPs only (defined as the  $-\log_{10}(P\text{-value})$ ) against the corresponding expected statistic. The grey area corresponds to the 90% confidence intervals calculated empirically using permutations. The meta-analysis inflation factors are: coronary heart disease ( $\lambda_s = 0.923$ ), HDL-C ( $\lambda_s = 1.030$ ), hypertension ( $\lambda_s = 1.121$ ), LDL-C ( $\lambda_s = 1.290$ ), smoking ( $\lambda_s = 1.060$ ), and type-2 diabetes ( $\lambda_s = 1.109$ ). Data shown is genomic controlled before (for each study) and after the meta-analysis.

Found at: doi:10.1371/journal.pgen.1001300.s004 (0.26 MB TIF)

**Figure S5** Manhattan plots summarizing the meta-analysis results that take into account local ancestry estimates and SNP genotypes (two degrees-of-freedom). Results are shown for the six phenotypes analyzed after double genomic control scaling. The dashed line highlights genome-wide significance ( $P\text{-value} = 5 \times 10^{-8}$ ). The genome-wide significant loci include *LCAT* (chr16) and *CETP* (chr16) for HDL-C and *PCSK9* (chr1), *CELSR2-PSRC1-SORT1* (chr1), 2p24 (chr2), and *APOE* (chr19) for LDL-C. Found at: doi:10.1371/journal.pgen.1001300.s005 (1.23 MB TIF)

**Figure S6** Comparison of P-values ( $-\log_{10}$  scale) for the meta-analysis results obtained using SNP genotype-only (x-axis) or SNP genotype+estimate of local ancestry (y-axis) to compute the test statistics. Each black circle corresponds to a SNP. In total, results from  $\sim 885,000$  genotyped SNPs were available for each method. The gray line represents perfect correlation ( $x = y$ ). The horizontal and vertical dashed lines represent the pre-defined threshold for genome-wide significance ( $P\text{-value} = 5 \times 10^{-8}$ ).

Found at: doi:10.1371/journal.pgen.1001300.s006 (0.45 MB TIF)

**Table S1** Sample exclusion for the CARE Affy6.0 datasets.

Found at: doi:10.1371/journal.pgen.1001300.s007 (0.05 MB DOC)

**Table S2** SNP exclusion for the CARE Affy6.0 datasets.

Found at: doi:10.1371/journal.pgen.1001300.s008 (0.04 MB DOC)

**Table S3** Power calculations for the different phenotypes analyzed by the CARE Project in this study. The assumptions

are: an additive inheritance model, an effect allele frequency of 10%, and an alpha threshold of  $1 \times 10^{-6}$  (which was arbitrary selected to promote SNPs for replication). We also assume that all samples belong to a single study; in practice, there is a small loss of power because of the meta-analysis. For case-control, power calculations were done using the Genetic Power Calculator (<http://pngu.mgh.harvard.edu/~purcell/gpc/>). For quantitative traits, power calculations were done using Quanto (<http://hydra.usc.edu/gxe/>).

Found at: doi:10.1371/journal.pgen.1001300.s009 (0.04 MB DOC)

**Table S4** Inflation factors ( $\lambda_s$ ) for the different phenotypes analyzed, by cohort and for the corresponding meta-analyses.

Found at: doi:10.1371/journal.pgen.1001300.s010 (0.04 MB DOC)

**Table S5** Coronary heart disease replication results for SNPs from the CARE meta-analysis.

Found at: doi:10.1371/journal.pgen.1001300.s011 (0.25 MB DOC)

**Table S6** HDL-C replication results for SNPs from the CARE meta-analysis.

Found at: doi:10.1371/journal.pgen.1001300.s012 (0.21 MB DOC)

**Table S7** Hypertension replication results for SNPs from the CARE meta-analysis.

Found at: doi:10.1371/journal.pgen.1001300.s013 (0.21 MB DOC)

**Table S8** LDL-C replication results for SNPs from the CARE meta-analysis.

Found at: doi:10.1371/journal.pgen.1001300.s014 (0.22 MB DOC)

**Table S9** Type-2 diabetes replication results for SNPs from the CARE meta-analysis.

Found at: doi:10.1371/journal.pgen.1001300.s015 (0.10 MB DOC)

## References

- NHLBI (2009) 2009 NHLBI Morbidity and Mortality Chart Book.
- Thomas J, Thomas DJ, Pearson T, Klag M, Mead L (1997) Cardiovascular disease in African American and white physicians: the Meharry Cohort and Meharry-Hopkins Cohort Studies. *J Health Care Poor Underserved* 8: 270–283; discussion 284.
- Jones DW, Chambless LE, Folsom AR, Heiss G, Hutchinson RG, et al. (2002) Risk factors for coronary heart disease in African Americans: the atherosclerosis risk in communities study, 1987–1997. *Arch Intern Med* 162: 2565–2571.
- Cooper R, Rotimi C (1997) Hypertension in blacks. *Am J Hypertens* 10: 804–812.
- Cooper RS, Zhu X (2001) Racial differences and the genetics of hypertension. *Curr Hypertens Rep* 3: 19–24.
- Katzmarzyk PT, Perusse L, Rice T, Gagnon J, Skinner JS, et al. (2000) Familial resemblance for coronary heart disease risk: the HERITAGE Family Study. *Ethn Dis* 10: 138–147.
- WTCCC (2007) Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 447: 661–678.
- Erdmann J, Grosshennig A, Braund PS, König IR, Hengstenberg C, et al. (2009) New susceptibility locus for coronary artery disease on chromosome 3q22.3. *Nat Genet* 41: 280–282.
- Helgadóttir A, Thorleifsson G, Manolescu A, Gretarsdóttir S, Blöndal T, et al. (2007) A common variant on chromosome 9p21 affects the risk of myocardial infarction. *Science* 316: 1491–1493.
- Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, et al. (2009) Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat Genet* 41: 334–341.
- McPherson R, Pertsemlidis A, Kavassalis N, Stewart A, Roberts R, et al. (2007) A common allele on chromosome 9 associated with coronary heart disease. *Science* 316: 1488–1491.
- Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, et al. (2007) Genome-wide association analysis of coronary artery disease. *N Engl J Med* 357: 443–453.
- Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, et al. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nat Genet* 40: 161–169.
- Gudbjartsson DF, Bjornsdóttir US, Halapi E, Helgadóttir A, Sulem P, et al. (2009) Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. *Nat Genet* 41: 342–347.
- Musunuru K, Lettre G, Young T, Farlow DN, Pirruccello JP, et al. (2010) Candidate gene association resource (CARE): design, methods, and proof of concept. *Circ Cardiovasc Genet* 3: 267–275.
- Korn JM, Kuruvilla FG, McCarroll SA, Wysoker A, Nemesh J, et al. (2008) Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. *Nat Genet* 40: 1253–1260.
- Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* 38: 904–909.
- Li Y, Willer C, Sanna S, Abecasis G (2009) Genotype imputation. *Annu Rev Genomics Hum Genet* 10: 387–406.
- Kang SJ, Chiang CW, Palmer CD, Tayo BO, Lettre G, et al. (2010) Genome-wide association of anthropometric traits in African- and African-derived populations. *Hum Mol Genet* 19: 2725–2738.
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81: 559–575.
- Chen MH, Yang Q (2009) GWAF: an R package for genome-wide association analyses with family data. *Bioinformatics*.
- Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 26: 2190–2191.

**Table S10** Loci associated at genome-wide significance level with CHD or its risk factors in Caucasians (data retrieved from the NHGRI database; <http://www.genome.gov/26525384>).

Found at: doi:10.1371/journal.pgen.1001300.s016 (0.30 MB DOC)

**Table S11** CARE meta-analysis association results (including data from ARIC, CARDIA, CFS, JHS, and MESA) for the SNPs associated with coronary heart disease and its risk factors in Caucasians. In yellow, we highlight the five loci where association signals in African Americans define smaller genomic intervals to search for causal allele(s).

Found at: doi:10.1371/journal.pgen.1001300.s017 (0.32 MB DOC)

**Table S12** Linkage disequilibrium-based genomic intervals of loci previously associated with coronary heart disease and HDL-C in Caucasians using the CARE datasets.

Found at: doi:10.1371/journal.pgen.1001300.s018 (0.05 MB DOC)

**Text S1** Supporting information.

Found at: doi:10.1371/journal.pgen.1001300.s019 (0.27 MB DOC)

## Acknowledgments

The authors wish to acknowledge the support of the National Heart, Lung, and Blood Institute and the contributions of the research institutions, study investigators, field staff, and study participants in creating this resource for biomedical research.

## Author Contributions

Conceived and designed the experiments: GL TY KGE SK EB. Performed the experiments: GL CDP KGE. Analyzed the data: GL CDP KGE SK EB. Contributed reagents/materials/analysis tools: GL CDP TY KGE HA EJB FB DWB AC AD DNF ARF MF TF EF CAH JH TBH SLH SRH BEH JNH BJK SBK EL ML MER CAM JBM YAM THM ABN CHNC DNP GJP NP WSP BMP ANQ LQ DJR SR MPR APR SSR JIR YL PS DSS WHWT HAT RPT RSV KMW RW JGW RRF SBG SK EB. Wrote the paper: GL EB.

23. Hindorf LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci U S A* 106: 9362–9367.
24. Adeyemo A, Gerry N, Chen G, Herbert A, Doumatey A, et al. (2009) A genome-wide association study of hypertension and blood pressure in African Americans. *PLoS Genet* 5: e1000564. doi:10.1371/journal.pgen.1000564.
25. Helgason A, Palsson S, Thorleifsson G, Grant SF, Emilsson V, et al. (2007) Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. *Nat Genet* 39: 218–225.
26. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. *Nat Genet* 41: 56–65.
27. Patterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, et al. (2004) Methods for high-density admixture mapping of disease genes. *Am J Hum Genet* 74: 979–1000.
28. Chen MH, Yang Q (2010) GWAf: an R package for genome-wide association analyses with family data. *Bioinformatics* 26: 580–581.
29. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, et al. (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. *Nat Genet* 40: 638–645.
30. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* 466: 707–713.
31. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, et al. (2009) Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nat Genet* 41: 47–55.
32. Kathiresan S, Melander O, Guiducci C, Surti A, Burt NP, et al. (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. *Nat Genet* 40: 189–197.
33. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, et al. (2010) LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* 26: 2336–2337.